Finance entity
Blend Labs is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. They are better corroborated than the beat average, carrying 3.5 original sources each against 2.6 for the same window. Their average consequence score of 5.5 runs below the beat's 6.3 for that window.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Blend Labs is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. They are better corroborated than the beat average, carrying 3.5 original sources each against 2.6 for the same window. Their average consequence score of 5.5 runs below the beat's 6.3 for that window. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Finance stories that mention SURO Capital, published between March 12, 2026 and March 17, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 612 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SURO Capital. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen has issued 'Sell' ratings for both SAB Biotherapeutics and SURO Capital, signaling a shift in sentiment for high-risk biotech and venture-backed assets. These downgrades reflect growing analyst caution regarding clinical-stage development timelines and private equity valuation gaps in the 2026 market environment.
The Q4 2025 earnings cycle reveals a pivot toward AI-driven operational efficiency and concrete commercialization timelines, led by Kodiak AI's driverless roadmap and Blend Labs' return to positive cash generation. Management teams across sectors are prioritizing leaner operating models and high-margin software integration to navigate the 2026 fiscal year.
SURO Capital is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
